Skip to main content
Publish date:

Worldwide Animal Vaccines Industry To 2028 - Rising Livestock Population And Pet Ownership Is Driving Growth

DUBLIN, Nov. 25, 2021 /PRNewswire/ -- The "Global Animal Vaccines Market Size, Share & Trends Analysis Report by Product, by Animal Type (Poultry, Aqua, Ruminants, Companion), by Region (North America, Europe, APAC, Latin America, MEA), and Segment...

DUBLIN, Nov. 25, 2021 /PRNewswire/ -- The "Global Animal Vaccines Market Size, Share & Trends Analysis Report by Product, by Animal Type (Poultry, Aqua, Ruminants, Companion), by Region (North America, Europe, APAC, Latin America, MEA), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global animal vaccines market size is expected to reach USD 16.1 billion by 2028. The market is expected to expand at a CAGR of 7.4% from 2021 to 2028. Rising concern about food security and increasing animal husbandry are boosting the demand for vaccines for the livestock population. Moreover, the growing demand for animal products, such as milk, chicken, eggs, and meat, is encouraging farmers to adopt vaccinations for their livestock to gain higher profitability.The increasing outbreaks of cattle disease and the ever-expanding livestock population are the prime factors for the wide acceptance of the ruminants especially cattle vaccines globally. Moreover, rising pet ownership and increasing awareness regarding the health of companion animals are further propelling the growth. Moreover, the increasing number of R&D investments initiated by the companies is one of the key potential growth factors.In June 2020, Boehringer Ingelheim received a new veterinary drug registration certificate from the Ministry of Agriculture & Rural Affairs of China for its classical swine fever vaccine. In July 2020, Biogenesis Bago partnered with the U.S. Department of Agriculture (USDA) as one of USDA's suppliers for antigens and vaccines for foot-and-mouth disease in livestock. Animal Vaccines Market Report Highlights

  • Attenuated vaccines emerged as the largest segment in 2020 as a result of the benefits such as improved effectiveness and enhanced long-term prevention
  • The ruminants segment accounted for the largest revenue share in 2020 owing to the rise in the demand for safe livestock products
  • The poultry segment dominated the market in 2020 owing to the increase in demand for meat, worldwide
  • North America dominated the market and accounted for the largest revenue share in 2020. Constantly rising awareness regarding livestock health and increasing commercialization of livestock products are factors expected to drive the market in the region during the forecast period
  • In Asia Pacific, the market is projected to witness swift growth during the forecast period owing to the speedy adoption of animal vaccines for quality food products and better animal health

Key Topics Covered: Chapter 1 Research Methodology & Scope Chapter 2 Executive Summary Chapter 3 Animal Vaccines Market Variables, Trends & Scope3.1 Market Lineage Outlook3.1.1 Parent market analysis3.2 Penetration & Growth Prospect Mapping3.3 Regulatory Framework3.4 Animal Vaccines Market Dynamics3.4.1 Market driver analysis3.4.1.1 Rising livestock population and pet ownership3.4.1.2 Increasing disease outbreaks3.4.1.3 Rising R&D and manufacturing procedural advancements3.4.1.4 Growing demand for animal-derived food products3.4.1.5 regulatory mandates3.4.2 Market restraint analysis3.4.2.1 Government intervention3.4.2.2 Short product exclusivity period3.4.2.3 high storage cost of vaccines3.5 Animal Vaccines Market Analysis Tools: Porters3.6 PESTEL Analysis3.7 Major Deals & Strategic Alliances Analysis Chapter 4 Animal Vaccines Market: Competitive Analysis4.1 Market Participation Categorization4.2 Public Companies4.2.1 Company market share/position analysis4.2.2 Competitive Dashboard Analysis4.3 Private Companies4.3.1 List of key emerging companies Chapter 5 Animal Vaccines Market: COVID Impact Analysis5.1 Impact of Disease Outbreak on The Market Chapter 6 Animal Vaccines Market: Product Estimates & Trend Analysis6.1 Product Market Share Analysis, 2020 & 20286.2 Product Dashboard6.3 Global Animal Vaccines Market, By Product, 2016 to 20286.3.1 Attenuated live vaccines6.3.1.1 Attenuated live vaccines market estimates and forecasts, 2016 - 2028 (USD Million)6.3.2 Inactivated vaccines6.3.2.1 Inactivated vaccines market estimates and forecasts, 2016 - 2028 (USD Million)6.3.3 Subunit vaccines6.3.3.1 Subunit vaccines market estimates and forecasts, 2016 - 2028 (USD Million)6.3.4 DNA vaccines6.3.4.1 DNA vaccines market estimates and forecasts, 2016 - 2028 (USD Million)6.3.5 Recombinant vaccines6.3.5.1 Recombinant vaccines market estimates and forecasts, 2016 - 2028 (USD Million) Chapter 7 Animal Vaccines Market: Animal type Estimates & Trend Analysis7.1 Animal Type Market Share Analysis, 2020 & 20287.2 Animal Type Dashboard7.2.1 Poultry7.2.1.1 Poultry Market by disease type7.2.1.2 Infectious bronchitis7.2.1.2.1 INFECTIOUS BRONCHITIS market estimates and forecasts, 2016 - 2028 (USD Million)7.2.1.3 Avian influenza7.2.1.3.1 Avian influenza market estimates and forecasts, 2016 - 2028 (USD Million)7.2.1.4 Marek's disease7.2.1.4.1 Marek's disease market estimates and forecasts, 2016 - 2028 (USD Million)7.2.1.5 Newcastle disease7.2.1.5.1 NEWCASTLE DISEASE market estimates and forecasts, 2016 - 2028 (USD Million)7.2.1.6 Salmonella7.2.1.6.1 Salmonella market estimates and forecasts, 2016 - 2028 (USD Million)7.2.1.7 Others7.2.1.7.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)7.2.2 Aqua7.2.2.1 Aqua Market by disease type7.2.2.2 Bacterial7.2.2.2.1 Bacterial market estimates and forecasts, 2016 - 2028 (USD Million)7.2.2.3 Viral7.2.2.3.1 Viral market estimates and forecasts, 2016 - 2028 (USD Million)7.2.2.4 Others7.2.2.4.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)7.2.3 Ruminants7.2.3.1 Ruminants Market by disease type7.2.3.2 Foot & mouth disease (FMD)7.2.3.2.1 FOOT & MOUTH DISEASE (FMD) market estimates and forecasts, 2016 - 2028 (USD Million)7.2.3.3 Lumpy skin7.2.3.3.1 Lumpy skin market estimates and forecasts, 2016 - 2028 (USD Million)7.2.3.4 Rotavirus7.2.3.4.1 Rotavirus market estimates and forecasts, 2016 - 2028 (USD Million)7.2.3.5 Coronavirus7.2.3.5.1 CORONAVIRUS drugs market estimates and forecasts, 2016 - 2028 (USD Million)7.2.3.6 E. COLI7.2.3.6.1 E. COLI market estimates and forecasts, 2016 - 2028 (USD Million)7.2.3.7 Others7.2.3.7.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4 Companion7.2.4.1 Canine Market by disease type7.2.4.2 Distemper7.2.4.2.1 DISTEMPER market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.3 Kennel cough7.2.4.3.1 Kennel cough market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.4 Parvovirus7.2.4.4.1 Parvovirus market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.5 Canine herpes7.2.4.5.1 CANINE HERPES drugs market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.6 Lyme disease7.2.4.6.1 Lyme disease market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.7 Rabies7.2.4.7.1 Rabies market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.8 Feline Market by disease type7.2.4.9 Rhinotracheitis7.2.4.9.1 Rhinotracheitis market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.10 Calicivirus7.2.4.10.1 Calicivirus market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.11 Corona virus7.2.4.11.1 Corona virus market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.12 Panleukopenia7.2.4.12.1 Panleukopenia market estimates and forecasts, 2016 - 2028 (USD Million)7.2.4.13 Rabies7.2.4.13.1 Rabies market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5 Swine7.2.5.1 Swine market estimates and forecasts, by disease type7.2.5.2 Swine influenza7.2.5.2.1 swine influenza market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.3 Classical Swine Fever (CSF)7.2.5.3.1 CSF market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.4 Porcine Parvovirus (PPV)7.2.5.4.1 PPV market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.5 Porcine Circovirus Type 2 (PCV2)7.2.5.5.1 PCV2 market estimates and forecasts, 2016 - 2028 (USD Million) 7.2.5.6 M. Hyo 7.2.5.6.1 M.Hyo market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.7 Actinobacillus Pleuropneumoniae7.2.5.7.1 Actinobacillus Pleuropneumoniae market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.8 PRRS7.2.5.8.1 PRRS market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.9 Foot & mouth disease7.2.5.9.1 FMD disease market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.10 Pseudorabies7.2.5.10.1 pseudorabies market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.11 PEDV (coronavirus)7.2.5.11.1 PEDV market estimates and forecasts, 2016 - 2028 (USD Million)7.2.5.12 Others7.2.5.12.1 Others market estimates and forecasts, 2016 - 2028 (USD Million) Chapter 8 Animal Vaccines Market: Regional Estimates & Trend Analysis, by, Product, Animal Type Chapter 9 Company Profiles9.1 Merck & Co., Inc.9.1.1 Company overview9.1.2 Financial performance9.1.3 Product benchmarking9.1.4 Strategic initiatives9.2 Zoetis9.2.1 Company overview9.2.2 Financial performance9.2.3 Product benchmarking9.2.4 Strategic initiatives9.3 Boehringer Ingelheim International GmbH9.3.1 Company overview9.3.2 Financial performance9.3.3 Product benchmarking9.3.4 Strategic initiatives9.4 Virbac9.4.1 Company overview9.4.2 Financial performance9.4.3 Product benchmarking9.4.4 Strategic initiatives9.5 Biogenesis Bago9.5.1 Company overview9.5.2 FINANCIAL PERFORMANCE9.5.3 Product benchmarking9.5.4 Strategic initiatives9.6 Indian Immunologicals Ltd.9.6.1 Company overview9.6.2 Product benchmarking9.6.3 Strategic initiatives9.7 Elanco9.7.1 Company overview9.7.2 Financial performance9.7.3 Product benchmarking9.7.4 Strategic initiatives9.8 Ceva9.8.1 Company overview9.8.2 FINANCIAL PERFORMANCE9.8.3 R&D Investment9.8.4 Product benchmarking9.8.5 Strategic initiatives9.9 Phibro Animal Health Corporation9.9.1 Company overview9.9.2 Financial performance9.9.3 Product benchmarking9.9.4 Strategic initiatives9.10 Neogen Corporation9.10.1 Company overview9.10.2 Financial performance9.10.3 Product benchmarking9.10.4 Strategic initiatives9.11 Intas Pharmaceuticals Ltd.9.11.1 Company overview9.11.2 Financial performance9.11.3 Product benchmarking9.11.4 Strategic initiatives9.12 Ourofino Saude Animal9.12.1 Company overview9.12.2 Financial performance9.12.3 Product benchmarking9.12.4 Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/z5tmgm

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content: https://www.prnewswire.com/news-releases/worldwide-animal-vaccines-industry-to-2028---rising-livestock-population-and-pet-ownership-is-driving-growth-301432181.html

SOURCE Research and Markets